Diagnostic Tools Gene Therapy Blood Testing Imaging Technology Vaccine Development Health Innovations Vaccine Technology Antimalarial Compounds Diagnostic Innovations Targeted Therapy mRNA Technology Diagnostics Organ Replacement Gene Editing Technology Cancer Treatment Technology Health Improvement Regenerative Medicine Tissue Engineering Drug Delivery Systems Research Methods Gene Editing Organ Printing Organ Transplants Transplant Technology Stem Cell Therapy Cancer Screening Implant Technology Targeted Therapies Gel Formation Drug Development Infection Prevention Artificial Intelligence Drug Innovation Reproductive Technology
The one-time in vivo candidate TSRA-196 targets correction of SERPINA1 mutations, with Tessera planning an FDA filing by year-end.
